Answers are grounded in this paper and cite their sources.
Emtricitabine (FTC) is a nucleoside analogue antiretroviral used in the treatment and prevention of human immunodeficiency virus (HIV) infection. Approximately 86% of the dose is excreted unchanged via the renal route, making it an emerging contaminant of increasing environmental relevance. This study presents a systematic review on the environmental fate of FTC in aquatic matrices, covering occurrence, transformation products, ecotoxicity, removal, and stability. Searches were performed in the Web of Science, Scopus, PubMed, and Google Scholar databases, with a final inclusion of 54 studies. FTC has been detected in different aquatic matrices on a global scale, at concentrations ranging from ng/L to μg/L, with high concentrations reported in wastewater treatment plants (WWTPs) in countries with high HIV prevalence, reaching up to 352,000 ng/L in the influent of South African WWTPs, with partial removal by conventional treatment. The transformation products carboxy-emtricitabine (FTC-COOH) and emtricitabine sulfoxide (FTC-S-oxide) were identified in effluents and water bodies, indicating environmental persistence. Ecotoxicity data are scarce, with EC50 values in the mg/L range, indicating low risk, although in combined formulations, the synergistic effect is greater than that of the isolated compound. Advanced removal technologies have been investigated, such as advanced oxidation processes (AOPs), activated carbon adsorption, and molecularly imprinted polymers (MIPs), with good removal performance. The results highlight critical gaps in the environmental risk assessment of FTC, particularly the absence of toxicity data for transformation products and the lack of environmental monitoring.
No takes yet. Share an insight, caveat, or question.
Miranda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: